Browse the full directors' dealings record of Cronos Group Inc., a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cronos Group Inc. has logged 7 insider filings. Market capitalisation: €1bn. The latest transaction was disclosed on 14 May 2026 — Levée d'options. Among the most active insiders: Wagner Adam. The full history is accessible without an account.
0 of 0 declarations
Cronos Group Inc. is an international cannabinoid company listed on the NASDAQ under the ticker CRON, in the United States. The business is rooted in Canada, where it was founded and built around branded cannabis products, research-led product development, and international market expansion. Its principal executive presence is in Toronto, Ontario, and the company reports operations across several jurisdictions, most notably Canada and Israel, with additional growth ambitions in Europe. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001656472/000165647226000016/cron-20251231.htm?utm_source=openai)) From an equity analyst perspective, Cronos is best understood as a branded consumer cannabis platform rather than a pure upstream cultivator. Its portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®, with products spanning dried flower, vapes, gummies, pre-rolls, and other cannabis formats. The company also emphasizes innovation in cannabinoid-based formulations, including products enhanced with rare cannabinoids, which supports differentiation in a category that remains structurally competitive and price-sensitive. ([ir.thecronosgroup.com](https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-unveils-new-spinachr-12g-vapes-and-sourz-spinachr-gummies/?utm_source=openai)) Cronos’ competitive position is strongest where brand equity and product innovation matter most. In Canada, Spinach has been particularly visible in vapes and edibles, while PEACE NATURALS has established itself as a leading medical cannabis brand in Israel. The company has also disclosed international commercialization efforts in markets such as Germany and the UK, reinforcing its positioning as a global cannabinoid company with multi-market optionality. ([ir.thecronosgroup.com](https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-group-reports-2026-first-quarter-results/?utm_source=openai)) Recent developments have been centered on product launches and share gains. In 2025, Cronos expanded Spinach with new vape and gummy formats infused with rare cannabinoids, and into early 2026 it reported that Spinach had reached the number-one vape position in Canada, while several SOURZ by Spinach gummies ranked among the top-selling edible products nationally. The company also highlighted a pending acquisition in the Netherlands that could provide a strategic foothold in Europe and broaden its international footprint. ([ir.thecronosgroup.com](https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-unveils-new-spinachr-12g-vapes-and-sourz-spinachr-gummies/?utm_source=openai)) Overall, Cronos Group is a specialized cannabis and cannabinoid name with meaningful brand assets, a multi-country footprint, and a NASDAQ listing in the United States. For investors, the key themes are execution in branded consumer products, international expansion, regulatory sensitivity, and the path toward sustained profitability and scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001656472/000165647226000016/cron-20251231.htm?utm_source=openai))